Company news

Vivani Medical, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vivani Medical Announces Publication of Positive Weight Loss Data Supporting Potential Veterinary Use of OKV-119 Miniature, Long-term GLP-1 Implant

May 27, 2024

Vivani Medical Provides Business Update and Reports First Quarter 2024 Financial Results

May 12, 2024

Vivani Medical to Present at TIDES Conference 2024

May 8, 2024

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

March 25, 2024

Vivani Medical Appoints Daniel Bradbury to its Board of Directors

March 5, 2024

Vivani Medical Announces Pricing of $15.0 Million Registered Direct Offering of Common Stock and Warrants

February 29, 2024

Vivani Medical Announces Positive NPM-115 Preclinical Weight Loss Data Comparable to Ozempic®/Wegovy® and Discloses NPM-139 as Semaglutide as Strategy Shifts to Prioritize Obesity Portfolio

February 27, 2024

Vivani Medical Provides Business Update and Reports Third Quarter Financial Results

November 13, 2023

Vivani Medical to Present at BIO Investor Forum

October 15, 2023

Vivani Medical to Present at the Boulder Peptide Symposium

September 6, 2023

Vivani Medical Subsidiary Cortigent to Present Orion Clinical Study Results at The Eye and The Chip World Research Congress on Artificial Vision October 8-10

September 4, 2023

Vivani Medical Reports Second Quarter Financial Results and Provides Business Update

August 13, 2023

Vivani Medical, Inc. Subsidiary Cortigent Reports 5-Year Early Feasibility Study Update for the Orion® Visual Cortical Prosthesis System

July 10, 2023

Vivani Medical to Participate in Panel Discussion at the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest

June 13, 2023

Vivani Medical Reports First Quarter Financial Results and Provides Business Update

May 14, 2023

Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study

April 3, 2023

Vivani Medical Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 30, 2023

Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division

March 20, 2023

Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates

November 13, 2022

Vivani Medical to Present at the ThinkEquity Investor Conference

October 16, 2022

Vivani Announces Trading under New Ticker Symbol (Nasdaq: VANI)

August 30, 2022

Second Sight Medical Products Announces Successful Completion of its Merger with Nano Precision Medical and its Name Change to Vivani Medical, Inc.

August 29, 2022

Second Sight Medical Products, Inc. Announces Shareholder Approval for Proposed Merger with Nano Precision Medical, Inc. and other Results of 2022 Annual Meeting

July 28, 2022

Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study

July 17, 2022

Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

February 6, 2022

Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

August 10, 2021

Second Sight Medical Products Announces Closing of Public Offering

June 24, 2021

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

June 21, 2021

Second Sight Medical Products Announces Pricing of Public Offering

June 21, 2021

Second Sight Medical Products Announces Results of its 2021 Annual Meeting

May 31, 2021

Second Sight Medical Products Announces Year Three NIH Funding of Its Orion Study

May 12, 2021

Second Sight Medical Products Announces Two-Year Results of its Orion Study

May 11, 2021

Second Sight Medical Products Names Dean Baker and Alexandra Larson to its Board of Directors

April 5, 2021

Second Sight Medical Products Names Scott Dunbar Acting CEO

March 31, 2021

Second Sight Medical Products Announces Closing of $27.9 Million Private Placement of Common Stock

March 25, 2021

Second Sight Medical Products Announces $27.9 Million Private Placement of Common Stock

March 23, 2021

Second Sight Medical Products, Inc. Receives FDA Approval for the Argus 2s Retinal Prosthesis System

March 4, 2021

Second Sight Medical Products Inc. Announces Resumption of Its Early Feasibility Study of the Orion® Cortical Visual Prosthesis at UCLA

September 21, 2020

Second Sight Medical Products Inc. Announces Closing of Public Offering of Common Stock

May 4, 2020

Second Sight Medical Products Announces Pricing of Public Offering of Common Stock

April 29, 2020

Second Sight Medical Products Provides Business Update

April 27, 2020

Second Sight Announces Employee Layoffs, Intent to Wind Down Operations and Appointment of Matthew Pfeffer as Acting CEO

March 29, 2020

Second Sight Reports Fourth Quarter and Full Year 2019 Financial Results

March 18, 2020

Second Sight to Discuss Fourth Quarter and Year-End 2019 Financial Results on March 19, 2020 Conference Call

March 15, 2020

Second Sight Announces Departure of Will McGuire, President and CEO, and Appointment of Gregg Williams as Acting CEO

March 11, 2020

Second Sight Reports Third Quarter 2019 Financial Results

November 13, 2019

Second Sight to Discuss Third Quarter 2019 Financial Results on November 14, 2019 Conference Call

November 4, 2019

Second Sight Announces $2.4 Million, Four-Year Grant from National Institutes of Health to Develop Spatial Localization and Mapping Technology

September 30, 2019

← Newer news releases

Decks

The 5 newest of 42 decks. Every deck is listed under its year.